Bone Biologics (BBLG) Research & Development (2014 - 2026)
Bone Biologics (BBLG) posted quarterly Research & Development of $257197.0 for Q4 2025, down 76.72% year-over-year from $1.1 million in Q4 2024, and up 36.95% quarter-over-quarter from $187808.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Research & Development (2014 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Research & Development for 12 consecutive years, with $257197.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 76.72% year-over-year to $257197.0; the TTM figure through Dec 2025 stood at $940980.0 (down 55.83% YoY), while the FY2025 annual figure was $1.1 million, down 50.23% from the prior year.
- Research & Development improved to $257197.0 in Q4 2025 per BBLG's latest filing, from $187808.0 in the prior quarter.
- Across five years, Research & Development topped out at $2.6 million in Q1 2023 and bottomed at $2016.0 in Q2 2021.
- Historically, Research & Development has averaged $612659.5 across 5 years, with a median of $304367.0 in 2025.
- Annual changes were most pronounced in 2023 — Research & Development surged 12941.2% — and 2024, when it slumped 90.52%.
- Bone Biologics' Research & Development stood at $34528.0 in 2021, then jumped by 2089.2% to $755888.0 in 2022, then plunged by 40.85% to $447077.0 in 2023, then surged by 147.07% to $1.1 million in 2024, then slumped by 76.72% to $257197.0 in 2025.
- Business Quant data shows BBLG's Research & Development at $257197.0 in Q4 2025, $187808.0 in Q3 2025, and $191608.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | 308,747.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 308,747.00 |
| Dec 31, 2025 | 257,197.00 |
| Sep 30, 2025 | 187,808.00 |
| Jun 30, 2025 | 191,608.00 |
| Mar 31, 2025 | 423,576.00 |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 429,747.00 |
| Jun 30, 2024 | 350,442.00 |
| Mar 31, 2024 | 245,625.00 |
| Dec 31, 2023 | 447,077.00 |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | 2.30 Mn |
| Mar 31, 2023 | 2.59 Mn |
| Dec 31, 2022 | 755,888.00 |
| Sep 30, 2022 | 769,410.00 |
| Jun 30, 2022 | 17,600.00 |
| Mar 31, 2022 | 36,400.00 |
| Dec 31, 2021 | 34,528.00 |
| Jun 30, 2021 | 2,016.00 |
| Mar 31, 2021 | 45,500.00 |